Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy

-
Investigator: Muhammad Y. Sheikh, MD
Sponsor: Salix Pharmaceuticals, Inc.

Location(s): United States

Description

The purpose of the study is to evaluate if Rifaximin alone or Rifaximin plus Lactulose delays the onset of hepatic encephalopathy (HE) in cirrhotic subjects who have had a previous episode of HE.